941710-30-1

Basic information

• Product Name: 7-BroMochroMan
• Synonyms: 7-BroMochroMan;7-bromo-3,4-dihydro-2H-chromene;2H-1-Benzopyran, 7-bromo-3,4-dihydro-
• CAS NO: 941710-30-1
• Molecular Formula: C9H9BrO
• Molecular Weight: 213.07116
• Mol File: 941710-30-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 263.3±29.0 °C(Predicted)
• Appearance: /
• Density: 1.484±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-BroMochroMan(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMochroMan(941710-30-1)
• EPA Substance Registry System: 7-BroMochroMan(941710-30-1)

Safety Data

• Hazardous Substances Data: 941710-30-1(Hazardous Substances Data)

Usage

General Description

7-Bromocholesterol (7-BroMochroMan) is a synthetic compound that acts as a modulator of the cellular cholesterol metabolism pathway. It is used in research to study the mechanisms of cholesterol trafficking within cells and its impact on membrane organization and functions. Specifically, 7-BroMochroMan is known to disrupt the formation of lipid rafts, which are essential for various cellular processes including signal transduction, membrane transport, and protein trafficking. 7-BroMochroMan has also been found to inhibit the intracellular transport of cholesterol, affecting its distribution and potentially influencing cellular homeostasis. Its unique properties make it a valuable tool for investigating the role of cholesterol in cellular physiology and disease.

Upstream product

• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 
• 1037206-46-4 1,4-dibromo-2-(3-bromopropanoxyl)benzene 
• 1435-52-5 2,5-dibromofluorobenzene 

Relevant articles and documents

SUBSTITUTED TRICYCLIC COMPOUNDS

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS

The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatr